Invention Grant
US09359372B2 Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof
有权
六氢二苯并[a，g]喹嗪化合物及其制备方法，药物组合物及其用途
![Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof](/docs/US/2016-06-07/US09359372B2/abs.jpg.600x600.jpg)
- Patent Title: Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof
- Patent Title (中): 六氢二苯并[a，g]喹嗪化合物及其制备方法，药物组合物及其用途
-
Application No.: US14683726Application Date: 2015-04-10
-
Publication No.: US09359372B2Publication Date: 2016-06-07
- Inventor: Hong Liu , Xin Xie , Xuechu Zhen , Haifeng Sun , Jing Li , Liyuan Zhu , Zeng Li , Ying Chen , Hualiang Jiang , Kaixian Chen
- Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- Applicant Address: CN Shanghai
- Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- Current Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- Current Assignee Address: CN Shanghai
- Agency: Panitch Schwarze Belisario & Nadel LLP
- Priority: CN201110141822 20110527
- Main IPC: A61K31/4741
- IPC: A61K31/4741 ; C07D491/12 ; C07D491/153 ; C07D455/03 ; C07D491/147 ; C07D491/22 ; C07C69/736 ; C07C231/14 ; C07D217/20 ; C07D311/20 ; C07D491/056
![Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof](/abs-image/US/2016/06/07/US09359372B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.
Public/Granted literature
Information query
IPC分类:
